A snapshot of the precision medicine landscape
What needs to happen to facilitate data sharing, ensure access to genome sequencing and promising personalized therapies?
After decades of determined research, RNAi drugs have their day in the sun
A panel at Biotech Showcase last week provided an outlook for a new class of drugs that only entered the market two years ago, but was decades in the making.
Integrating GLP-1s: How Berry Street is Redefining Nutrition Care
Richard Fu details the company's approach to nutrition therapy and strategy for patients using GLP-1s.
PBM rebates lower premiums for healthy people, but don’t bring down drug costs, BMS chief says
A panel discussion at the 2020 J.P. Morgan Healthcare Conference brought together industry executives to talk about the issue of high drug prices. The conference concluded Thursday.
Foundation Medicine touts concordance ahead of FDA ruling on liquid biopsy test
The company filed for FDA approval of the FoundationOne Liquid test at the end of December. Data from a clinical trial presented at an October conference showed the test had a strong ability to detect a genetic driver mutation in lung cancer.
BMS execs upbeat on anticipated CAR-T therapy launches
In a breakout session at the J.P. Morgan Healthcare Conference Monday, the company's executive team was optimistic about manufacturing and reimbursement for its CAR-Ts to treat lymphoma and multiple myeloma.
Novartis, UK’s NHS form population health partnership around new cholesterol drug
The deal will make the Phase III drug inclisiran - which Novartis acquired when it bought The Medicines Company in November - available to patients in the U.K. and include manufacturing and clinical development efforts.
Transforming the OR: CEO Reveals Game-Changing AI Tech for Better Efficiency
How Apella leverages technology to increase OR efficiency.